ALL
MCID: LKM062
MIFTS: 70

Leukemia, Acute Lymphoblastic (ALL)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Leukemia, Acute Lymphoblastic

MalaCards integrated aliases for Leukemia, Acute Lymphoblastic:

Name: Leukemia, Acute Lymphoblastic 58 76 13 13 13 13 39
Acute Lymphoblastic Leukemia 39 77 54 30 6 17
Leukemia, Acute Lymphoblastic, Susceptibility to 30 13 6
All 58 54 76
Leukemia, T-Cell Acute Lymphoblastic 13 41
B-Cell Acute Lymphoblastic Leukemia 38 17
Acute Lymphocytic Leukemia 54 74
Leukemia, Acute Lymphoblastic, Susceptibility to, 3 74
Leukemia, Acute Lymphocytic, Susceptibility to, 1 58
Precursor Cell Lymphoblastic Leukemia-Lymphoma 45
Precursor Cell Lymphoblastic Leukemia Lymphoma 74
Leukemia Acute Lymphoblastic B-Hyperdiploid 76
Childhood Acute Lymphoblastic Leukemia 76
Leukemia, Acute, Lymphoblastic, T-Cell 41
Leukemia, Acute T-Cell Lymphoblastic 13
Leukemia B-Cell Acute Lymphoblastic 76
Leukemia T-Cell Acute Lymphoblastic 76
Leukemia, Acute Lymphoblastic, 3 76
Leukemia, Lymphocytic, Acute, L1 74
Leukemia Acute Lymphoblastic 1 76
Leukemia, Acute, Lymphoblastic 41
Leukemia, Acute Lymphocytic 1 58
Leukemia Acute Lymphocytic 1 76
Lymphoblastic Leukemia Acute 56
Leukemia, Acute Lymphocytic 13
Leukemia Acute Lymphocytic 76
All3 76
All1 76

Characteristics:

HPO:

33
leukemia, acute lymphoblastic:
Inheritance polygenic inheritance


Classifications:



Summaries for Leukemia, Acute Lymphoblastic

NIH Rare Diseases : 54 Acute lymphoblastic leukemia (ALL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). It may develop in children or adults. ALL spreads to the blood fairly quickly, and then may spread to other areas of the body such as the lymph nodes, liver, spleen, central nervous system, and testicles (in males). Signs and symptoms of ALL may include fever, easy bruising or bleeding, feeling tired, loss of appetite, pain in the bones or abdomen, and painless lumps in the neck, underarm, stomach, or groin. ALL is typically caused by random, non-inherited changes in the DNA of immature lymphocytes called lymphoblasts. However, some people may inherit a genetic susceptibility to developing ALL. The risk to develop ALL may also be increased by past treatment for cancer, and by having certain genetic conditions or syndromes. Having one or more risk factors does not mean that a person definitely will develop ALL. Treatment of ALL depends on the person's age, how advanced the cancer is, and whether certain genetic changes are found in cancer cells. Treatment options may involve systemic and/or intrathecal chemotherapy, radiation therapy, targeted therapy, and/or a stem cell transplant. Biologic therapy and chimeric antigen receptor (CAR) T-cell therapy are currently being studied as treatment options and may be used when other therapies are not working. The chance of recovery also depends on many factors. With treatment, about 98% of children with ALL go into remission, and 85% of those with first-time ALL are expected have no long-term complications. The chance of recovery for adults is not as high, as 20-40% of adults are cured with current treatments.

MalaCards based summary : Leukemia, Acute Lymphoblastic, also known as acute lymphoblastic leukemia, is related to leukemia, acute lymphoblastic 3 and prostate cancer, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Leukemia, Acute Lymphoblastic is NBN (Nibrin), and among its related pathways/superpathways are Transcriptional misregulation in cancer and MicroRNAs in cancer. The drugs Methotrexate and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are acute lymphoblastic leukemia and neoplasm

OMIM : 58 Acute lymphoblastic leukemia (ALL), also known as acute lymphocytic leukemia, is a subtype of acute leukemia, a cancer of the white blood cells. Somatically acquired mutations in several genes have been identified in ALL lymphoblasts, cells in the early stages of differentiation. Germline variation in certain genes may also predispose to susceptibility to ALL (Trevino et al., 2009). (613065)

UniProtKB/Swiss-Prot : 76 Leukemia, acute lymphoblastic: A subtype of acute leukemia, a cancer of the white blood cells. ALL is a malignant disease of bone marrow and the most common malignancy diagnosed in children. The malignant cells are lymphoid precursor cells (lymphoblasts) that are arrested in an early stage of development. The lymphoblasts replace the normal marrow elements, resulting in a marked decrease in the production of normal blood cells. Consequently, anemia, thrombocytopenia, and neutropenia occur to varying degrees. The lymphoblasts also proliferate in organs other than the marrow, particularly the liver, spleen, and lymphnodes. Leukemia, acute lymphoblastic, 3: A subtype of acute leukemia, a cancer of the white blood cells. Acute lymphoblastic anemia is a malignant disease of bone marrow and the most common malignancy diagnosed in children. The malignant cells are lymphoid precursor cells (lymphoblasts) that are arrested in an early stage of development. The lymphoblasts replace the normal marrow elements, resulting in a marked decrease in the production of normal blood cells. Consequently, anemia, thrombocytopenia, and neutropenia occur to varying degrees. The lymphoblasts also proliferate in organs other than the marrow, particularly the liver, spleen, and lymphnodes.

Wikipedia : 77 Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid line of blood cells characterized by the... more...

Related Diseases for Leukemia, Acute Lymphoblastic

Diseases in the Leukemia, Acute Lymphoblastic family:

Leukemia, Acute Lymphoblastic 2 Leukemia, Acute Lymphoblastic 3

Diseases related to Leukemia, Acute Lymphoblastic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 668)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute lymphoblastic 3 34.4 ETV6 FLT3 PAX5
2 prostate cancer 31.1 MIR199B MIR203A MIR23A MIR23B MIR27A MIRLET7B
3 bone marrow cancer 30.5 ETV6 FLT3 MIR155
4 melanoma 30.5 MIR199B MIR23B MIR27A MIRLET7B MIRLET7E
5 lymphoid leukemia 30.4 ETV6 FLT3 GNB1 NBN
6 acute leukemia 30.3 ETV6 FLT3 PAX5
7 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 30.2 ETV6 FLT3
8 dermatomyositis 30.1 MIR155 MIR199B
9 leukemia, acute myeloid 29.9 ETV6 FLT3 MIR130B MIR155 MIR199B MIR23A
10 hepatocellular carcinoma 29.7 MIR152 MIR155 MIR199B MIR203A MIR23A MIR23B
11 acute lymphoblastic leukemia, childhood 12.9
12 b-cell childhood acute lymphoblastic leukemia 12.7
13 adult acute lymphocytic leukemia 12.6
14 precursor t-cell acute lymphoblastic leukemia 12.5
15 leukemia, acute lymphoblastic 2 12.4
16 acute lymphoblastic leukemia congenital sporadic aniridia 12.3
17 acute t cell leukemia 12.1
18 t-cell childhood acute lymphocytic leukemia 12.1
19 b-cell adult acute lymphocytic leukemia 11.9
20 null-cell leukemia 11.8
21 lymphoblastic lymphoma 11.7
22 childhood leukemia 11.7
23 acute lymphocytic leukemia 11.7
24 bone marrow necrosis 11.7
25 medulloblastoma 11.6
26 lymphoblastic leukemia, acute, with lymphomatous features 11.6
27 precursor lymphoblastic lymphoma/leukemia 11.6
28 t-cell adult acute lymphocytic leukemia 11.3
29 hematopoietic stem cell transplantation 10.8
30 lymphocytic leukemia 10.7
31 leukemia 10.7
32 down syndrome 10.6
33 osteonecrosis 10.6
34 glucocorticoid resistance, generalized 10.5
35 caronte 10.5
36 sarcoma 10.5
37 mucositis 10.5
38 lymphoma, hodgkin, classic 10.5
39 lymphoma, non-hodgkin, familial 10.5
40 thrombosis 10.5
41 neuropathy 10.5
42 pancreatitis 10.5
43 wilms tumor 5 10.5
44 wilms tumor 6 10.5
45 neutropenia 10.5
46 graft-versus-host disease 10.4
47 mucormycosis 10.4
48 burkitt lymphoma 10.4
49 encephalopathy 10.4
50 facioscapulohumeral muscular dystrophy 1 10.4 MIR155 MIR199B MIRLET7B

Graphical network of the top 20 diseases related to Leukemia, Acute Lymphoblastic:



Diseases related to Leukemia, Acute Lymphoblastic

Symptoms & Phenotypes for Leukemia, Acute Lymphoblastic

Human phenotypes related to Leukemia, Acute Lymphoblastic:

33
# Description HPO Frequency HPO Source Accession
1 acute lymphoblastic leukemia 33 HP:0006721

Clinical features from OMIM:

613065

UMLS symptoms related to Leukemia, Acute Lymphoblastic:


angina pectoris, edema, chest pain

MGI Mouse Phenotypes related to Leukemia, Acute Lymphoblastic:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.1 ACTB ETV6 FLT3 NBN PAX5 PMS2

Drugs & Therapeutics for Leukemia, Acute Lymphoblastic

Drugs for Leukemia, Acute Lymphoblastic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 654)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
2
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
3
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 302962-49-8 3062316
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1177-87-3
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
6
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
7
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58957-92-9 42890
8
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 20830-81-3 30323
9
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 147-94-4, 65-46-3 6253
10
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2068-78-2, 57-22-7 5978
11
Mercaptopurine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-44-2 667490
12
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65271-80-9 4212
13
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-23-7 5754
14
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-03-3
15
Teniposide Approved Phase 4,Phase 3,Phase 2,Not Applicable 29767-20-2 34698
16
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
17
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
18
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
19
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
20
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
21
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
22
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 174722-31-7 10201696
23
Sargramostim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 123774-72-1, 83869-56-1
24
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
25
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 130167-69-0
26
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
27
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 59917-39-4, 53643-48-4 40839
28
Thioguanine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154-42-7 2723601
29
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
30
Cladribine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 4291-63-8 20279
31
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 3778-73-2 3690
32
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
33
Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
34
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 55-98-1 2478
35
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
36
Micafungin Approved, Investigational Phase 4,Phase 2 235114-32-6 477468 3081921
37
Posaconazole Approved, Investigational, Vet_approved Phase 4,Not Applicable 171228-49-2 147912
38
Methylphenidate Approved, Investigational Phase 4,Not Applicable 113-45-1 4158
39
Dopamine Approved Phase 4,Not Applicable 62-31-7, 51-61-6 681
40
Oprelvekin Approved, Investigational Phase 4 145941-26-0
41
inotuzumab ozogamicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 635715-01-4
42
Azacitidine Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 320-67-2 9444
43
Decitabine Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 2353-33-5 451668
44
Morphine Approved, Investigational Phase 4,Phase 3,Not Applicable 57-27-2 5288826
45
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2 1397-89-3 14956 5280965
46
Nicotine Approved Phase 4 54-11-5 942 89594
47
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
48
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
49
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 50-14-6 5280793
50
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 1406-16-2

Interventional clinical trials:

(show top 50) (show all 1867)
# Name Status NCT ID Phase Drugs
1 Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
2 Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
3 The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
4 Treatment of High Risk Adult Acute Lymphoblastic Leukemia Unknown status NCT00853008 Phase 4 Vincristine;Daunorubicin;Prednisone;Mitoxantrone;Cytosine Arabinoside;Dexamethasone;Methotrexate (MTX);Cytarabine;ASP;Mercaptopurine;Teniposide;Hydrocortisone
5 German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
6 Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
7 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
8 Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
9 Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses Unknown status NCT00192673 Phase 4 PEG-asparaginase
10 HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
11 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
12 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
13 Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4 vincristine;dexamethasone
14 Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia Completed NCT01358253 Phase 4 Cyclophosphamide;Doxorubicin;Vincristine;Dexamethasone;Cytarabine;Methotrexate;Rituximab;6-Mercaptopurine;Prednisone;L-asparaginase
15 LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia Completed NCT00526409 Phase 4 Prednisolone;Daunorubicin;Vincristine;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside
16 PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Completed NCT00494897 Phase 4 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin;Mercaptopurine;Prednisone;Vincristine;Methotrexate
17 Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia Completed NCT00199095 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone;Idarubicin;Ifosfamide;Methotrexate;Mercaptopurine;VM26;Vincristine
18 LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive Completed NCT00526305 Phase 4 Vincristine;Daunorubicin;Prednisone;L-Asparaginase;Mitoxantrone;Cytosine Arabinoside;Hydrocortisone;Mercaptopurine;Cyclophosphamide;Dexamethasone
19 ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
20 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93) Completed NCT00199069 Phase 4 Asparaginase;Vincristine;Daunorubicin, Adriamycin;Cyclophosphamide;Ifosfamide;Cytarabine;Mitoxantrone;Methotrexate;6-Mercaptopurine;6-Thioguanine;VM26;Dexamethasone / Prednisolone
21 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99) Completed NCT00199056 Phase 4 Dexamethasone / Prednisolone;Cyclophosphamide;Methotrexate;Vincristine / Vindesine;Daunorubicin;Asparaginase;G-CSF;Cytarabine;6-Mercaptopurine;VP16;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Ifosfamide
22 Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab Completed NCT00199004 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Vincristine;Daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Adriamycin;Thioguanine;VM26;Rituximab
23 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
24 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4 Methylphenidate
25 LAL-BR/2001: Study Treatment to Low Risk ALL Completed NCT00526175 Phase 4 Prednisone;Vincristine;Daunorubicin;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside;Mercaptopurine;VP-16
26 Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL Completed NCT02314273 Phase 4 rhIL-11
27 The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents Completed NCT02953730 Phase 4 PEG-rhG-CSF
28 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
29 German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults Completed NCT00199017 Phase 4 Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine
30 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
31 Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase Completed NCT01061177 Phase 4 Nilotinib
32 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
33 Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years) Recruiting NCT01366898 Phase 4 Dexamethasona, Idarubicine, ARA-C, Methotrexate
34 A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients Recruiting NCT03677596 Phase 4 inotuzumab ozogamicin-dose level 2;Inotuzumab ozogamicin-dose level 1
35 Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE Recruiting NCT01491763 Phase 4 Imatinib
36 Study on Two Different Formulations of 6-mercaptopurine. Tablet Versus Oral Liquid Recruiting NCT01906671 Phase 4 Xaluprine;Puri-Nethol
37 PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years Recruiting NCT01358201 Phase 4 vINCRISTINE;Dexamethasone;Methotrexate;Cytosine arabinoside
38 ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
39 Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Recruiting NCT02036489 Phase 4 Vincristine;Daunorubicin;Prednisone;L-asparaginase;Ciclophosphamide;Metotrexate;ARA-C;Hidrocortisone;Mercaptopurine;VP-16;Dexametasone
40 ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors Recruiting NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
41 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Recruiting NCT02933333 Phase 4
42 A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma Recruiting NCT03558412 Phase 4 Decitabine
43 Vaccinating Children After Chemotherapy Active, not recruiting NCT02447718 Phase 4
44 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Enrolling by invitation NCT03176849 Phase 4
45 ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia Terminated NCT00386997 Phase 4 liposomal amphotericin B (AmBisome®)
46 Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL Terminated NCT00299234 Phase 4 Atomoxetine
47 Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients Unknown status NCT02042690 Phase 3 Chemotherapy
48 Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Naïve Acute Lymphoblastic Leukemia Unknown status NCT02072785 Phase 3 Vincristine Sulfate Liposome;Vincristine Sulfate
49 Treatment of Acute Lymphoblastic Leukemia or Aggressive Lymphoma With Relapse in Central Nervous System With Depocyt Unknown status NCT00199108 Phase 2, Phase 3 Depocyt;Dexamethasone
50 High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL) Unknown status NCT00131027 Phase 3 Cyclophosphamide;Daunorubicin;Vincristine;Prednisolone;L-asparaginase;Cytarabine;Etoposide;Dexamethasone;Methotrexate;Mercaptopurine;Doxorubicin;Methotrexate

Search NIH Clinical Center for Leukemia, Acute Lymphoblastic

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Acute Lymphoblastic cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: precursor cell lymphoblastic leukemia-lymphoma

Genetic Tests for Leukemia, Acute Lymphoblastic

Genetic tests related to Leukemia, Acute Lymphoblastic:

# Genetic test Affiliating Genes
1 Leukemia, Acute Lymphoblastic, Susceptibility to 30
2 Acute Lymphoblastic Leukemia 30

Anatomical Context for Leukemia, Acute Lymphoblastic

MalaCards organs/tissues related to Leukemia, Acute Lymphoblastic:

42
T Cells, B Cells, Bone, Bone Marrow, Myeloid, Kidney, Testes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Acute Lymphoblastic:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease
3 Blood Hematopoietic Bone Marrow Small Pre B-Cells Affected by disease

Publications for Leukemia, Acute Lymphoblastic

Articles related to Leukemia, Acute Lymphoblastic:

(show top 50) (show all 7776)
# Title Authors Year
1
Insulin-dependent diabetes: A chronic complication to acute pancreatitis in childhood acute lymphoblastic leukemia. ( 30216644 )
2019
2
Bilateral trifocal IOL implantation in a pediatric case of cataract following steroid-therapy for acute lymphoblastic leukemia. ( 30555958 )
2019
3
Congenital B-cell Acute Lymphoblastic Leukemia with Congenital Rubella Infection. ( 30806367 )
2019
4
Monitoring of cytomegalovirus infection in non-transplant pediatric acute lymphoblastic leukemia patients during chemotherapy. ( 30681620 )
2019
5
Development of acute lymphoblastic leukemia following treatment for acute myeloid leukemia in children with Down syndrome: A case report and retrospective review of Children's Oncology Group acute myeloid leukemia trials. ( 30908863 )
2019
6
Dasatinib and low-intensity chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia in a child with Down syndrome. ( 30663211 )
2019
7
Feasibility and Potential Benefits of an Exercise Intervention in a Male With Down Syndrome Undergoing High-Dose Chemotherapy for Acute Lymphoblastic Leukemia: A Case Report. ( 30795696 )
2019
8
Posterior reversible encephalopathy syndrome in children with acute lymphoblastic leukemia: Experience of a single center using BFM protocols. ( 30868749 )
2019
9
Invasive fusariosis masquerading as extramedullary disease in rapidly progressive acute lymphoblastic leukemia. ( 30900813 )
2019
10
Growth hormone deficiency and neurocognitive function in adult survivors of childhood acute lymphoblastic leukemia. ( 30690723 )
2019
11
Hematopoietic Stem Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group. ( 30742559 )
2019
12
Access to Hematopoietic Stem Cell Transplantation among Pediatric Patients with Acute Lymphoblastic Leukemia: A Population-based Analysis. ( 30769192 )
2019
13
Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia. ( 30806963 )
2019
14
Higher Reported Lung Dose Received during Total Body Irradiation for Allogeneic Hematopoietic Stem Cell Transplantation in Children with Acute Lymphoblastic Leukemia is Associated with Inferior Survival: A Report from the Children's Oncology Group. ( 30807822 )
2019
15
Chimeric Antigen Receptor-modified Donor Lymphocyte Infusion Improves the Survival of Acute Lymphoblastic Leukemia Patients With Relapsed Diseases After Allogeneic Hematopoietic Stem Cell Transplantation. ( 30829725 )
2019
16
Paraneoplastic hypereosinophilic syndrome associated with IL3-IgH positive acute lymphoblastic leukemia. ( 30207070 )
2019
17
Allopurinol reverses mercaptopurine-induced hypoglycemia in patients with acute lymphoblastic leukemia. ( 30828444 )
2019
18
Type B Lactic Acidosis: A Rare Initial Presentation of Childhood Acute Lymphoblastic Leukemia. ( 30814800 )
2019
19
Successful Treatment of Pyoderma Gangrenosum With Skin Grafting in a Patient With Acute Lymphoblastic Leukemia. ( 30882508 )
2019
20
Intrathecal dose intensification by CNS status at diagnosis in the treatment of children with acute lymphoblastic leukemia. ( 30885098 )
2019
21
A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia. ( 30890593 )
2019
22
Timosaponin A‑III induces autophagy of T‑cell acute lymphoblastic leukemia Jurkat cells via inhibition of the PI3K/Akt/mTOR pathway. ( 30896824 )
2019
23
Umbilical cord blood‑derived Helios‑positive regulatory T cells promote angiogenesis in acute lymphoblastic leukemia in mice via CCL22 and the VEGFA‑VEGFR2 pathway. ( 30896872 )
2019
24
Absolute Lymphocyte Count at End of Induction as a Surrogate Marker for Minimal Residual Disease in T Acute Lymphoblastic Leukemia: A pilot study. ( 30898988 )
2019
25
Metabolomics of Neonatal Blood Spots Reveal Distinct Phenotypes of Pediatric Acute Lymphoblastic Leukemia and Potential Effects of Early-life Nutrition. ( 30904619 )
2019
26
Bone Loss in Pediatric Survivors of Acute Lymphoblastic Leukemia. ( 30911254 )
2019
27
WP1130 reveals USP24 as a novel target in T-cell acute lymphoblastic leukemia. ( 30911287 )
2019
28
The effect of adopting pediatric protocols in adolescents and young adults with acute lymphoblastic leukemia in pediatric vs adult centers: An IMPACT Cohort study. ( 30912628 )
2019
29
A cross-sectional follow-up study of physical morbidities, neurocognitive function, and attention problems in post-treatment childhood acute lymphoblastic leukemia survivors. ( 30913362 )
2019
30
Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. ( 30916583 )
2019
31
Relapsed B-Acute Lymphoblastic Leukemia with Aberrant Myeloperoxidase Expression Following CAR T-cell Therapy: A Diagnostic Challenge. ( 30916805 )
2019
32
Absolute count of leukemic blasts in cerebrospinal fluid as detected by flow cytometry is a relevant prognostic factor in children with acute lymphoblastic leukemia. ( 30840196 )
2019
33
Reduced vs. standard dose native E. coli-asparaginase therapy in childhood acute lymphoblastic leukemia: long-term results of the randomized trial Moscow-Berlin 2002. ( 30840197 )
2019
34
Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia: Early Diagnosis and New Treatment Strategies. ( 30842156 )
2019
35
Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. ( 30842605 )
2019
36
PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia. ( 30842609 )
2019
37
Clinician Concepts of Cure in Adult Relapsed and Refractory Philadelphia-Negative B Cell Precursor Acute Lymphoblastic Leukemia: A Delphi Study. ( 30847777 )
2019
38
No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy. ( 30848065 )
2019
39
A genetic variant in miR-100 is a protective factor of childhood acute lymphoblastic leukemia. ( 30848099 )
2019
40
Decreased Early Mortality in Young Adult Patients With Acute Lymphoblastic Leukemia Treated at Specialized Cancer Centers in California. ( 30849003 )
2019
41
Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation. ( 30849662 )
2019
42
A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia. ( 30850736 )
2019
43
Anterior segment infiltration of acute lymphoblastic leukemia: case report and systematic review. ( 30851770 )
2019
44
Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. ( 30858550 )
2019
45
Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma. ( 30859374 )
2019
46
GATA3 germline variant is associated with CRLF2 expression and predicts outcome in pediatric B-cell precursor acute lymphoblastic leukemia. ( 30859636 )
2019
47
Bovine Colostrum Against Chemotherapy-Induced Gastrointestinal Toxicity in Children With Acute Lymphoblastic Leukemia: A Randomized, Double-Blind, Placebo-Controlled Trial. ( 30861163 )
2019
48
Targeting the thioredoxin system as a novel strategy against B cell acute lymphoblastic leukemia. ( 30861284 )
2019
49
BCL-2 is a Therapeutic Target For Hypodiploid B-Lineage Acute Lymphoblastic Leukemia. ( 30862722 )
2019
50
Integrated analysis of relapsed B-cell precursor Acute Lymphoblastic Leukemia identifies subtype-specific cytokine and metabolic signatures. ( 30862934 )
2019

Variations for Leukemia, Acute Lymphoblastic

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Acute Lymphoblastic:

76
# Symbol AA change Variation ID SNP ID
1 PAX5 p.Gly183Ser VAR_070682 rs398123063

ClinVar genetic disease variations for Leukemia, Acute Lymphoblastic:

6 (show all 43)
# Gene Variation Type Significance SNP ID Assembly Location
1 NBN NM_002485.4(NBN): c.2140C> T (p.Arg714Ter) single nucleotide variant Pathogenic/Likely pathogenic rs730881864 GRCh38 Chromosome 8, 89943297: 89943297
2 NBN NM_002485.4(NBN): c.2140C> T (p.Arg714Ter) single nucleotide variant Pathogenic/Likely pathogenic rs730881864 GRCh37 Chromosome 8, 90955525: 90955525
3 ETV6 NM_001987.4(ETV6): c.1153-5_1153-1delAACAG deletion Pathogenic rs786205154 GRCh37 Chromosome 12, 12038855: 12038859
4 ETV6 NM_001987.4(ETV6): c.1153-5_1153-1delAACAG deletion Pathogenic rs786205154 GRCh38 Chromosome 12, 11885921: 11885925
5 ETV6 NM_001987.4(ETV6): c.1046T> C (p.Leu349Pro) single nucleotide variant Pathogenic rs786205155 GRCh37 Chromosome 12, 12037415: 12037415
6 ETV6 NM_001987.4(ETV6): c.1046T> C (p.Leu349Pro) single nucleotide variant Pathogenic rs786205155 GRCh38 Chromosome 12, 11884481: 11884481
7 ACTB NP_001092.1(ACTB): p.Val209Leu protein only Pathogenic
8 NBN NM_002485.4(NBN): c.511A> G (p.Ile171Val) single nucleotide variant risk factor rs61754966 GRCh37 Chromosome 8, 90990521: 90990521
9 NBN NM_002485.4(NBN): c.511A> G (p.Ile171Val) single nucleotide variant risk factor rs61754966 GRCh38 Chromosome 8, 89978293: 89978293
10 HOXD4 NM_014621.2(HOXD4): c.242A> T (p.Glu81Val) single nucleotide variant Uncertain significance rs104893636 GRCh37 Chromosome 2, 177016603: 177016603
11 HOXD4 NM_014621.2(HOXD4): c.242A> T (p.Glu81Val) single nucleotide variant Uncertain significance rs104893636 GRCh38 Chromosome 2, 176151875: 176151875
12 FLT3 NM_004119.2(FLT3): c.2504A> T (p.Asp835Val) single nucleotide variant Pathogenic rs121909646 GRCh37 Chromosome 13, 28592641: 28592641
13 FLT3 NM_004119.2(FLT3): c.2504A> T (p.Asp835Val) single nucleotide variant Pathogenic rs121909646 GRCh38 Chromosome 13, 28018504: 28018504
14 FLT3 NM_004119.2(FLT3): c.2503G> T (p.Asp835Tyr) single nucleotide variant Pathogenic rs121913488 GRCh37 Chromosome 13, 28592642: 28592642
15 FLT3 NM_004119.2(FLT3): c.2503G> T (p.Asp835Tyr) single nucleotide variant Pathogenic rs121913488 GRCh38 Chromosome 13, 28018505: 28018505
16 FLT3 NM_004119.2(FLT3): c.1777_1779del (p.Asp593del) deletion Pathogenic rs587776834 GRCh38 Chromosome 13, 28034140: 28034142
17 FLT3 NM_004119.2(FLT3): c.1777_1779del (p.Asp593del) deletion Pathogenic rs587776834 GRCh37 Chromosome 13, 28608277: 28608279
18 PMS2 NM_000535.6(PMS2): c.1831dup (p.Ile611Asnfs) duplication Pathogenic rs63750250 GRCh37 Chromosome 7, 6026565: 6026565
19 PMS2 NM_000535.6(PMS2): c.1831dup (p.Ile611Asnfs) duplication Pathogenic rs63750250 GRCh38 Chromosome 7, 5986934: 5986934
20 NBN NM_002485.4(NBN): c.1262T> C (p.Leu421Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs104895032 GRCh37 Chromosome 8, 90967646: 90967646
21 NBN NM_002485.4(NBN): c.1262T> C (p.Leu421Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs104895032 GRCh38 Chromosome 8, 89955418: 89955418
22 NBN NM_002485.4(NBN): c.1262T> C (p.Leu421Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs104895032 NCBI36 Chromosome 8, 91036822: 91036822
23 NBN NM_002485.4(NBN): c.628G> T (p.Val210Phe) single nucleotide variant Conflicting interpretations of pathogenicity rs61754796 GRCh37 Chromosome 8, 90983475: 90983475
24 NBN NM_002485.4(NBN): c.628G> T (p.Val210Phe) single nucleotide variant Conflicting interpretations of pathogenicity rs61754796 GRCh38 Chromosome 8, 89971247: 89971247
25 NBN NM_002485.4(NBN): c.628G> T (p.Val210Phe) single nucleotide variant Conflicting interpretations of pathogenicity rs61754796 NCBI36 Chromosome 8, 91052651: 91052651
26 NBN NM_002485.4(NBN): c.1999T> C (p.Ser667Pro) single nucleotide variant Uncertain significance rs587780091 GRCh37 Chromosome 8, 90958439: 90958439
27 NBN NM_002485.4(NBN): c.1999T> C (p.Ser667Pro) single nucleotide variant Uncertain significance rs587780091 GRCh38 Chromosome 8, 89946211: 89946211
28 NBN NM_002485.4(NBN): c.2149A> T (p.Thr717Ser) single nucleotide variant Uncertain significance rs587780093 GRCh37 Chromosome 8, 90955516: 90955516
29 NBN NM_002485.4(NBN): c.2149A> T (p.Thr717Ser) single nucleotide variant Uncertain significance rs587780093 GRCh38 Chromosome 8, 89943288: 89943288
30 NBN NM_002485.4(NBN): c.425A> G (p.Asn142Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs769414 GRCh37 Chromosome 8, 90993017: 90993017
31 NBN NM_002485.4(NBN): c.425A> G (p.Asn142Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs769414 GRCh38 Chromosome 8, 89980789: 89980789
32 NBN NM_002485.4(NBN): c.456G> A (p.Met152Ile) single nucleotide variant Uncertain significance rs201816949 GRCh37 Chromosome 8, 90992986: 90992986
33 NBN NM_002485.4(NBN): c.456G> A (p.Met152Ile) single nucleotide variant Uncertain significance rs201816949 GRCh38 Chromosome 8, 89980758: 89980758
34 NBN NM_002485.4(NBN): c.595C> T (p.Pro199Ser) single nucleotide variant Uncertain significance rs587780097 GRCh37 Chromosome 8, 90983508: 90983508
35 NBN NM_002485.4(NBN): c.595C> T (p.Pro199Ser) single nucleotide variant Uncertain significance rs587780097 GRCh38 Chromosome 8, 89971280: 89971280
36 GNB1 NM_002074.4(GNB1): c.239T> A (p.Ile80Asn) single nucleotide variant Pathogenic/Likely pathogenic rs752746786 GRCh37 Chromosome 1, 1737942: 1737942
37 GNB1 NM_002074.4(GNB1): c.239T> A (p.Ile80Asn) single nucleotide variant Pathogenic/Likely pathogenic rs752746786 GRCh38 Chromosome 1, 1806503: 1806503
38 GNB1 NM_002074.4(GNB1): c.227A> G (p.Asp76Gly) single nucleotide variant Pathogenic/Likely pathogenic rs869312821 GRCh38 Chromosome 1, 1806515: 1806515
39 GNB1 NM_002074.4(GNB1): c.227A> G (p.Asp76Gly) single nucleotide variant Pathogenic/Likely pathogenic rs869312821 GRCh37 Chromosome 1, 1737954: 1737954
40 NBN NM_002485.4(NBN): c.156_157delTT (p.Ser53Cysfs) deletion Pathogenic/Likely pathogenic rs767454740 GRCh38 Chromosome 8, 89982736: 89982737
41 NBN NM_002485.4(NBN): c.156_157delTT (p.Ser53Cysfs) deletion Pathogenic/Likely pathogenic rs767454740 GRCh37 Chromosome 8, 90994964: 90994965
42 PAX5 NM_016734.2(PAX5): c.435G> C (p.Gln145His) single nucleotide variant Uncertain significance GRCh38 Chromosome 9, 37006513: 37006513
43 PAX5 NM_016734.2(PAX5): c.435G> C (p.Gln145His) single nucleotide variant Uncertain significance GRCh37 Chromosome 9, 37006510: 37006510

Copy number variations for Leukemia, Acute Lymphoblastic from CNVD:

7 (show top 50) (show all 2943)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13316 1 1 117600000 Loss Acute lymphoblastic leukemia
2 13371 17 1 22200000 Deletion TP53 Acute lymphoblastic leukemia
3 13410 1 1 2300000 Copy number Acute lymphoblastic leukemia
4 13773 1 1 35400000 Duplication Acute lymphoblastic leukemia
5 13788 1 1 40300000 Duplication Acute lymphoblastic leukemia
6 13790 1 1 46500000 Gain Acute lymphoblastic leukemia
7 13836 12 10000000 12600000 Deletion ETV6 Acute lymphoblastic leukemia
8 13906 1 100818677 103024856 Loss DPH5 Acute lymphoblastic leukemia
9 13907 1 100818677 103024856 Loss EXTL2 Acute lymphoblastic leukemia
10 13908 1 100818677 103024856 Loss OLFM3 Acute lymphoblastic leukemia
11 13909 1 100818677 103024856 Loss S1PR1 Acute lymphoblastic leukemia
12 13910 1 100818677 103024856 Loss SLC30A7 Acute lymphoblastic leukemia
13 13911 1 100818677 103024856 Loss VCAM1 Acute lymphoblastic leukemia
14 13991 1 102370195 102561809 Deletion Acute lymphoblastic leukemia
15 14292 1 106673274 107678605 Loss NTNG1 Acute lymphoblastic leukemia
16 14293 1 106673274 107678605 Loss PRMT6 Acute lymphoblastic leukemia
17 14369 1 107716342 144004701 Loss ADAM30 Acute lymphoblastic leukemia
18 14370 1 107716342 144004701 Loss ADORA3 Acute lymphoblastic leukemia
19 14371 1 107716342 144004701 Loss AFARP1 Acute lymphoblastic leukemia
20 14372 1 107716342 144004701 Loss AHCYL1 Acute lymphoblastic leukemia
21 14373 1 107716342 144004701 Loss AKNAD1 Acute lymphoblastic leukemia
22 14374 1 107716342 144004701 Loss ALX3 Acute lymphoblastic leukemia
23 14375 1 107716342 144004701 Loss AMIGO1 Acute lymphoblastic leukemia
24 14376 1 107716342 144004701 Loss AMPD1 Acute lymphoblastic leukemia
25 14377 1 107716342 144004701 Loss AMPD2 Acute lymphoblastic leukemia
26 14378 1 107716342 144004701 Loss AP4B1 Acute lymphoblastic leukemia
27 14379 1 107716342 144004701 Loss ATP1A1 Acute lymphoblastic leukemia
28 14380 1 107716342 144004701 Loss ATP5F1 Acute lymphoblastic leukemia
29 14381 1 107716342 144004701 Loss ATXN7L2 Acute lymphoblastic leukemia
30 14382 1 107716342 144004701 Loss BCAS2 Acute lymphoblastic leukemia
31 14383 1 107716342 144004701 Loss BCL2L15 Acute lymphoblastic leukemia
32 14384 1 107716342 144004701 Loss C1orf103 Acute lymphoblastic leukemia
33 14385 1 107716342 144004701 Loss C1orf152 Acute lymphoblastic leukemia
34 14386 1 107716342 144004701 Loss C1orf161 Acute lymphoblastic leukemia
35 14387 1 107716342 144004701 Loss C1orf162 Acute lymphoblastic leukemia
36 14388 1 107716342 144004701 Loss C1orf183 Acute lymphoblastic leukemia
37 15383 1 115048600 115061038 Copy number NRAS Acute lymphoblastic leukemia
38 15429 1 115400000 222100000 Gain Acute lymphoblastic leukemia
39 15832 1 119869201 120436800 Loss HMGCS2 Acute lymphoblastic leukemia
40 15833 1 119869201 120436800 Loss NBPF7 Acute lymphoblastic leukemia
41 15834 1 119869201 120436800 Loss NOTCH2 Acute lymphoblastic leukemia
42 15835 1 119869201 120436800 Loss PHGDH Acute lymphoblastic leukemia
43 15836 1 119869201 120436800 Loss REG4 Acute lymphoblastic leukemia
44 15837 1 119869201 120436800 Loss ZNF697 Acute lymphoblastic leukemia
45 15979 1 120700000 169100000 Loss CREG1 Acute lymphoblastic leukemia
46 16426 1 124300000 247249719 Deletion Acute lymphoblastic leukemia
47 16427 1 124300000 247249719 Duplication Acute lymphoblastic leukemia
48 16474 1 125000000 249250621 Copy number Acute lymphoblastic leukemia
49 16502 1 12600000 16100000 Deletion Acute lymphoblastic leukemia
50 16592 1 128000000 185104377 Copy number Acute lymphoblastic leukemia

Expression for Leukemia, Acute Lymphoblastic

Search GEO for disease gene expression data for Leukemia, Acute Lymphoblastic.

Pathways for Leukemia, Acute Lymphoblastic

Pathways related to Leukemia, Acute Lymphoblastic according to KEGG:

38
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

Pathways related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.8 MIR152 MIR155 MIR199B MIR203A MIR23A MIR23B
2 10.96 MIR203A MIR23A MIR23B MIR27A
3 10.78 MIRLET7B MIRLET7C MIRLET7E
4 10.6 ETV6 FLT3

GO Terms for Leukemia, Acute Lymphoblastic

Cellular components related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 ACTB MIR130B MIR152 MIR155 MIR199B MIR23A
2 micro-ribonucleoprotein complex GO:0035068 9.32 MIR152 MIR155 MIR199B MIR203A MIR23A MIR23B

Biological processes related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.55 FLT3 MIR23A MIR23B MIR27A MIRLET7B
2 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.5 MIR23A MIR23B MIR27A
3 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.43 MIR23A MIR23B MIR27A
4 cell growth involved in cardiac muscle cell development GO:0061049 9.4 MIR23A MIR23B
5 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.37 MIR155 MIR27A
6 gene silencing by miRNA GO:0035195 9.36 MIR130B MIR152 MIR155 MIR199B MIR203A MIR23A
7 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.26 MIR23A MIR23B MIR27A MIRLET7B

Molecular functions related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.36 MIR130B MIR152 MIR155 MIR199B MIR203A MIR23A

Sources for Leukemia, Acute Lymphoblastic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....